Clinical Trial Update: Safety, Tolerability and Pharmacokinetics of Increasing Doses of BIIL 284 BS in Adult and Pediatric Cystic Fibrosis (CF) Patients [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluated safety, tolerability, and pharmacokinetics of escalating doses of BIIL 284 BS in adult and pediatric cystic fibrosis patients; the stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• BIIL 284 BS

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Cystic Fibrosis | Phase 1 | Status: COMPLETED